Chairs

Cheryl Ho, MD, FRCP(C)

Clinical Assistant Professor of Medicine, UBC
Medical Oncologist, BC Cancer Agency
Vancouver, BC

Cheryl Ho is a clinical assistant professor at the University of British Columbia and a medical oncologist at the British Columbia Cancer Agency.

She is currently the provincial systemic chair for head and neck malignancies.

She completed medical school and internal medicine training at the University of Western Ontario.

She is a graduate of the BC Cancer Agency Medical Oncology program and completed a fellowship in Thoracic Oncology at University of California, Davis.

Her current practice focuses on the treatment of thoracic and head and neck malignancies.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer Agency
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist at the British Columbia Cancer Agency.
She graduated from medical school at the University of Manitoba and did a residency in internal medicine at the University of British Columbia.

She is currently a medical oncologist at the BC Cancer Agency with clinical interests in GI and respiratory malignancies.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Faculty

Ronald Burkes, MD, FRCPC

Professor of Medicine, University of Toronto
Staff Medical Oncologist
Mount Sinai Hospital/Princess Margaret Hospital/UHN
Toronto, ON

Ron Burkes is Professor of Medicine at The University of Toronto and staff medical oncologist at Mount Sinai Hospital/Princess Margaret Hospital/University Health Network in Toronto.

He was the program director for the medical oncology training program at the University of Toronto from 1996 to 2005 and director of the Clinical Teaching Unit at PMH from 1999 to 2005. He has won numerous teaching awards including departmental and university wide awards on 13 occasions, the Anderson Award in Program Development and the Hasselback Teaching Award at PMH. He has presented at many local, provincial, national and international meetings.

His research interests include lung and GI malignancies and he has numerous publications including 76 peer reviewed, 126 non-peer reviewed and 2 book chapters.

Martin Robert Chasen

Associate Professor, Division of Palliative Care, University of Ottawa
Medical Director, Palliative Care,
William Osler Health System
Medical Director, Palliative Rehabilitation, Élisabeth Bruyère Hospital
Brampton, Ontario

Dr. Martin Chasen is currently the Medical Director of Palliative Care, at William Osler Health System in Brampton. He was previously Medical Director, Palliative Care, at The Ottawa Hospital Cancer Centre and the Palliative Rehabilitation Program at Élisabeth Bruyère Hospital, Ottawa.

Dr. Chasen, born in Pretoria, South Africa completed his undergraduate training in medicine and surgery at the University of Pretoria in 1983, later obtaining a specialist degree in Internal Medicine and Medical Oncology and Master of Philosophy (Palliative Medicine) at the University of Cape Town, South Africa. He is a founding member of the palliative care working group European Society of Medical Oncology and faculty member of ESMO education. In 2009, Dr. Chasen, was Team Leader and Physician, Cancer Nutrition & Rehabilitation Program at McGill University Hospital Complex obtained “Supra regionale de niveau 3” status for the PQCCC.  In 2013, Dr. Chasen and the team at Ottawa Hospital cancer centre achieved ESMO Designated Centre of Integrated Oncology and Palliative care.

 

He currently holds professorships at the Universities of Toronto, McMaster, Ottawa and McGill. He recently received the Elizabeth J Latimer Prize in Palliative Care from Mc Master University.

 

He has in excess of 100 peer reviewed publications, abstracts and book chapters. Dr. Chasen is the principle investigator of CIHR (Canadian Institutes of Health Research). This MENAC (The Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia), trial will investigate the addition of the multimodal intervention for patients receiving standard chemotherapy for metastatic cancer. He was also one of the chief investigators for the initial clinical trials on the use of Rolapitant-a novel NKI inhibitor in the treatment of chemo therapy induced nausea and vomiting.

Dr. Chasen has lectured nationally and internationally on rehabilitation of patients with cancer, approaches to treatment of patients with cachexia, chemotherapy induced nausea and vomiting, survivorship and symptom relief.

Dr Chasen was the Regional Palliative care physician lead for Palliative Care- Champlain LHIN from 2009-2015 and is presently the Medical co-lead for the Palliative Care Network in the Central West LHIN.

Peter Ellis, MBBS, MMed(Clin Epi), PhD, FRACP, FRCPC

Associate Professor, Dept. of Oncology & Clinical Epidemiology & Biostatistics
McMaster University
Medical Oncologists, Juravinski Cancer Centre
Hamilton, ON

Dr Ellis is an Associate Professor in the Departments of Oncology and Clinical Epidemiology & Biostatistics at McMaster University.  He is also a staff medical oncologist at the Juravinski Cancer Centre (JCC).  He obtained his medical degree at the University of Sydney. He completed a Masters of Medicine (Clinical Epidemiology) and a PhD also at the University of Sydney.  Dr Ellis moved to Canada in October, 2000.  He is the Chair of the JCC Lung Disease Site Team, an Executive Member of the National Cancer Institute of Canada (NCIC) Clinical Trials Group Lung Disease Site Committee, and is Co-Chair of Cancer Care Ontario’s Practice Guideline Initiative, Provincial Lung Disease Site Group.  He is also an investigator on several NCIC and pharmaceutical industry-sponsored multicentre phase III clinical trials in breast and lung cancer

Vera Hirsh, MD, FRCP(C)

Professor, Department of Medical Oncology
McGill University
Royal Victoria Hospital
Montreal, QC

Dr. Hirsh received her medical degree from Charles University in Prague, Czechoslovakia. She did a rotating internship and a two-year residency in Internal Medicine at Huntington Memorial Hospital – University of Southern California, U.S.A.

She then completed her residency in Hematology at the Royal Victoria Hospital – McGill University, Montreal, Canada. Her current practice includes both Hematology and Oncology. She is Chief of Hematology-Oncology Service at Santa Cabrini Hospital in Montreal.

She is also Associate Physician, Oncology Service, at the Royal Victoria and Montreal General Hospitals as well as Associate Professor of Oncology at McGill University. She has been chairing the Lung Cancer Committee of the McGill Department of Oncology since 1994. She has also chaired the Quebec Lung Cancer Committee to establish the guidelines for treatment of lung cancer.
She chaired five consecutive chemotherapy Phase I/II trials in lung cancer through the Quebec Pulmonary Unit and is chairing ongoing Quebec chemotherapy trials. She is a member of the Medical Oncology and Lung Cancer Core Committees of RTOG and the Data Safety Monitoring Board (DSMB) for all phase I and II trials.

She is a member of Editorial Boards for, Frontiers in Oncology and the World Journal of Clinical Oncology. She is a reviewer of many journals including Lung Cancer, Cancer, Clinical Lung Cancer and Annals of Oncology.

She is a member of global and national advisory boards for pharmaceutical companies. She was a chair of NCIC BR-14 Phase III trial comparing Platinum regimens with Gemcitabine/Vinorelbine in NSCLC Stage IIIB and IV.

She was a member of Steering Committees of international trials, i.e. AZ INTEREST trial, Roche CERA trial, Pfizer TLR-9 trial, Zephyr phase III trial, BIBW 2992 phase III third-line trial and is presently on Steering Committee of Sorafenib phase III trial, Pfizer phase III trial with ALK mutation agent, BIBW 2992 phase III first-line trial in lung cancer.

She has also authored over 200 publications which include articles, book chapters and abstracts.

Diana N. Ionescu, MD, FRCP(C), FCAP

Consultant Pathologist BC Cancer Agency Medical Director Clinical Trials, BCCA
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC
AP Residency Program Director
University of British Columbia
Vancouver, BC

Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and serves as the residency program director for the Anatomic Pathology Residency Program.

Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 35 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) course director.

Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy campaigns, being an Medical Advisor for Lung Cancer Canada and most recently appearing before the House of Commons Committee on Health.

Stephen Lam, MD, FRCPC

Professor of Medicine, Respiratory Division, UBC
Chair, Lung Tumour Group, BC Cancer Agency
Vancouver, BC

Dr. Lam is Professor of Medicine at UBC in the Respiratory Division. He is currently Chair of the Lung Tumour Group and directs the MDS-Rix Early Lung Cancer Detection and Translational Research Program at the BC Cancer Agency. He is a Distinguished Scientist in the Department of Integrative Oncology at the BC Cancer Research Centre. Dr. Lam’s research interest is in early detection, chemo prevention, endoscopic diagnosis and treatment of lung cancer. He was the recipient of the Joseph Cullen Award for life – time scientific achievements in lung cancer prevention research by the International Association for the Study of Lung Cancer and the UBC Killam Award.

Natasha B Leighl, MD, MMSc, FRCPC

Medical Oncologist, Princess Margaret Hospital
Associate Professor, Department of Medicine
University of Toronto
Toronto, ON

Dr. Natasha Leighl is a medical oncologist at the Princess Margaret Hospital, Toronto, Canada, and Associate Professor in the Department of Medicine at the University of Toronto, Toronto, Canada.

After receiving her MD from the University of Toronto, Dr. Leighl completed residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed a Fellowship in Thoracic Oncology with Dr Frances Shepherd at the Princess Margaret Hospital, a Fellowship in Clinical Oncology with Professor Martin Tattersall at the University of Sydney, Australia, and received her MMSc in Clinical Epidemiology at the University of Newcastle, Australia.

Dr. Leighl’s main interest is in developing new treatments in lung cancer. She is a member of the Lung Disease Site Executive and co-chairs the Committee on Economic Analysis in the NCIC Clinical Trials Group. Dr. Leighl is currently Web Editor of the Journal of Thoracic Oncology, Section Co-Editor of The Oncologist and Current Oncology and a member of the editorial board of the Journal of Clinical Oncology. She has served on several committees including as Lung Track Leader for the American Society of Clinical Oncology (ASCO) Cancer Education Committee, the Royal College of Physicians and Surgeons of Canada Medical Oncology Examination Board and the International Association for the Study of Lung Cancer (IASLC) Career Development and Continuing Education Committees. She is currently President of Lung Cancer Canada and has recently been awarded the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at the University Health Network, University of Toronto.

Randeep Sangha, MD, FRCPC

Medical Oncologist, Cross Cancer Institute
Assistant Professor, University of Alberta
Edmonton, AB

Dr. Sangha is a Thoracic Medical Oncologist at the Cross Cancer Institute and an Assistant Professor at the University of Alberta. He is the Lead for the Provincial Lung Tumor Group in Alberta.

After completing his residency in Internal Medicine and Medical Oncology at the University of Alberta, he pursued a post-training research fellowship at the University of California, Davis under the mentorship of Dr. David Gandara, focusing on thoracic malignancies.

Currently, his clinical and research interests are in the treatment of thoracic and hematological malignancies as well as Phase I developmental and molecular therapeutics.

Devin Schellenberg, MD, FRCS(C)

Clinical Instructor, Radiation Oncologist
Department of Radiation Oncology
BC Cancer Agency, Abbotsford Centre & Fraser Valley Centre
Vancouver, BC

Dr. Devin Schellenberg is a radiation oncologist practicing in the Fraser Valley and Abbotsford Cancer Centres. He is currently the head of the Clinical Trials Unit at the Abbotsford Cancer Centre and is one of the leaders in the British Columbia stereotactic radiation working group.

His radiation oncology residency was carried out at Princess Margaret Hospital in Toronto and the BC Cancer Agency, after which he completed a fellowship in stereotactic body radiation therapy at Stanford University in 2007.

His present research is focused on the use of novel imaging modalities in radiation therapy.

John Yee, MD, FRCS(C)

Assistant Professor- Division of Thoracic Surgery, UBC
Director- Lung Transplant Program, VGH
Vancouver, BC

Dr. John Yee is an Assistant Professor-Division of Thoracic Surgery, UBC and Director- Lung Transplant Program, VGH.

Dr. Yee is a designate of the Chair of the UBC Department of Surgery for the Surgical Oncology Network Council Executive.

Kelly Zibrik, MScN, RN

Coordinator, Lung Tumor Group
BC Cancer Agency
Vancouver, BC

Kelly Zibrik received her Bachelor in Science in Nursing degree from the University of British Columbia in 2002 and a Masters degree in Nursing from the University of Northern British Columbia in 2009. She has worked at the BC Cancer Agency since 2004 in various clinical nursing roles and is currently working as a nurse triage coordinator with the lung tumor group at the Vancouver Centre.